METHSUXIMIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Methsuximide, and what generic alternatives are available?
Methsuximide is a drug marketed by Novitium Pharma and is included in one NDA.
The generic ingredient in METHSUXIMIDE is methsuximide. Two suppliers are listed for this compound. Additional details are available on the methsuximide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Methsuximide
A generic version of METHSUXIMIDE was approved as methsuximide by NOVITIUM PHARMA on May 1st, 2023.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METHSUXIMIDE?
- What are the global sales for METHSUXIMIDE?
- What is Average Wholesale Price for METHSUXIMIDE?
Summary for METHSUXIMIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 67 |
| Patent Applications: | 2,935 |
| DailyMed Link: | METHSUXIMIDE at DailyMed |
Pharmacology for METHSUXIMIDE
| Drug Class | Anti-epileptic Agent |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
US Patents and Regulatory Information for METHSUXIMIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novitium Pharma | METHSUXIMIDE | methsuximide | CAPSULE;ORAL | 217213-001 | May 1, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
